![]() ![]() ENGAGE and EMERGE are global Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate the efficacy and safety of aducanumab. Driven by our steadfast commitment to patients and our strong business foundation, we will continue advancing our pipeline of potential therapies in Alzheimer’s disease and innovative medicines for patients suffering from diseases of high unmet need.”ĭetailed data from the ENGAGE and EMERGE studies will be presented at future medical meetings to inform ongoing research. “Biogen’s history has been based on pioneering innovation, learning from successes and setbacks. We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly to this research,” said Michel Vounatsos, Chief Executive Officer at Biogen. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. The recommendation to stop the studies was not based on safety concerns. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trialsĬAMBRIDGE, Mass., Ma(GLOBE NEWSWIRE) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. ![]()
0 Comments
Leave a Reply. |